Literature DB >> 12527586

Lung cancer. Palliative care.

Paul A Kvale1, Michael Simoff, Udaya B S Prakash.   

Abstract

The majority of patients who acquire lung cancer will have troublesome symptoms at some time during the course of their disease. Some of the symptoms are common to many types of cancers, while others are more often encountered with lung cancer than other primary sites. The most common symptoms are pain, dyspnea, and cough. This document will address the management of these symptoms, and it will also address the palliation of specific problems that are commonly seen in lung cancer: metastases to the brain, spinal cord, and bones; hemoptysis; tracheoesophageal fistula; and obstruction of the superior vena cava.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12527586     DOI: 10.1378/chest.123.1_suppl.284s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  27 in total

1.  Physiotherapy practice and delegation policies in oxygen administration: a survey of ontario hospitals.

Authors:  Olivia Espiritu; Erin Schaeffer; Natasha Bhesania; Sarah Perera; Emma Dickinson; Ethne Nussbaum; Denise Lai
Journal:  Physiother Can       Date:  2009-07-16       Impact factor: 1.037

Review 2.  The management of dyspnea in cancer patients: a systematic review.

Authors:  Raymond Viola; Cathy Kiteley; Nancy S Lloyd; Jean A Mackay; Julie Wilson; Rebecca K S Wong
Journal:  Support Care Cancer       Date:  2008-01-24       Impact factor: 3.603

3.  Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2/Snail signaling pathway.

Authors:  Ya-Ling Hsu; Ming-Shyan Huang; Chih-Jen Yang; Jen-Yu Hung; Ling-Yu Wu; Po-Lin Kuo
Journal:  J Biol Chem       Date:  2011-09-01       Impact factor: 5.157

Review 4.  Bronchoscopic advances in the management of aerodigestive fistulas.

Authors:  Houssein A Youness; Kassem Harris; Ahmed Awab; Jean I Keddissi
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

5.  Behaviour of mesenchymal stem cells from bone marrow of untreated advanced breast and lung cancer patients without bone osteolytic metastasis.

Authors:  Valeria B Fernández Vallone; Erica L Hofer; Hosoon Choi; Raúl H Bordenave; Emilio Batagelj; Leonardo Feldman; Vincent La Russa; Daniela Caramutti; Federico Dimase; Vivian Labovsky; Leandro M Martínez; Norma A Chasseing
Journal:  Clin Exp Metastasis       Date:  2012-09-30       Impact factor: 5.150

6.  Management of superior vena cava syndrome in critically ill cancer patients.

Authors:  Sarah Morin; Adeline Grateau; Danielle Reuter; Eric de Kerviler; Constance de Margerie-Mellon; Cédric de Bazelaire; Lara Zafrani; Benoit Schlemmer; Elie Azoulay; Emmanuel Canet
Journal:  Support Care Cancer       Date:  2017-08-24       Impact factor: 3.603

7.  Prognostic factors for patients in postoperative brain metastases from surgically resected non-small cell lung cancer.

Authors:  Jin Sakamoto; Makoto Sonobe; Masashi Kobayashi; Masashi Ishikawa; Ryutaro Kikuchi; Daisuke Nakajima; Tetsu Yamada; Ei Nakayama; Tsuyoshi Takahashi; Toshihiko Sato; Fengshi Chen; Toru Bando; Hiroshi Date
Journal:  Int J Clin Oncol       Date:  2012-12-14       Impact factor: 3.402

8.  Endoscopic Management of Esophagorespiratory Fistulas: A Multicenter Retrospective Study of Techniques and Outcomes.

Authors:  Bryan Silon; Ali A Siddiqui; Linda Jo Taylor; Sanaa Arastu; Ammara Soomro; Douglas G Adler
Journal:  Dig Dis Sci       Date:  2016-12-23       Impact factor: 3.199

9.  Bronchoscopic findings and bleeding control predict survival in patients with solid malignancies presenting with mild hemoptysis.

Authors:  Horiana B Grosu; Roberto F Casal; Rodolfo C Morice; Graciela M Nogueras-González; Georgie A Eapen; David Ost; Mona G Sarkiss; Carlos A Jimenez
Journal:  Ann Am Thorac Soc       Date:  2013-08

10.  Current status of thermal ablation treatments for lung malignancies.

Authors:  Damian E Dupuy; Maria Shulman
Journal:  Semin Intervent Radiol       Date:  2010-09       Impact factor: 1.513

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.